Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1613 1626 1651 1732
This examiner grants 71% of resolved cases
Michelle F. Paguio Frising serves in Tech Center 1700 and Art Unit 1613, where she has overseen 580 resolved cases. Her allowance rate of 71.0 percent suggests a path to grant for many applications. The 580 resolved cases provide a stable foundation for evaluating these performance metrics in Art Unit 1613.
A critical data point for practitioners is the interview lift pct of 39.4. This 39.4 percent increase in allowance probability following an interview is a significant impact seen in Art Unit 1613. Utilizing this 39.4 percent lift could be a decisive factor in overcoming initial rejections during prosecution.
The median days to allowance for this examiner is 947. This 947 day timeline represents the typical duration from filing to grant across the 580 resolved cases. Combining the 71.0 percent allowance rate with the interview lift suggests that active participation in the interview process is effective for securing a patent within the 947 day median window in Tech Center 1700.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18628290 | Bile Acids and Use in Disease Treatment | Final Rejection | The Regents of the University of California |
| 18570348 | ANTIBODY ANALYSIS METHOD | Non-Final OA | Shimadzu Corporation |
| 18718521 | SGK1 INHIBITORY COMPOSITIONS AND METHODS | Non-Final OA | Arizona Board of Regents on Behalf of the University of Arizona |
| 18552457 | CATALYTICALLY INACTIVE CLOSTRIDIAL NEUROTOXINS FOR THE TREATMENT OF PAIN & INFLAMMATORY DISORDERS | Non-Final OA | IPSEN BIOPHARM LIMITED |
| 18691035 | METHOD OF MITIGATION OF INJURIES CAUSED BY SYSTEMIC GENOTOXIC STRESS | Non-Final OA | Health Research, Inc. |
| 18655896 | Methods for Preparation of a Terminally Sterilized Hydrogel Derived from Extracellular Matrix | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18268477 | IMPROVED RECEPTOR-BINDING DOMAIN OF BOTULINUM NEUROTOXIN A AND USES THEREOF | Non-Final OA | Children's Medical Center Corporation |
| 18413541 | METHODS AND PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISEASES AND DISORDERS | Non-Final OA | RESEARCH DEVELOPMENT FOUNDATION |
| 18392662 | TREATMENT OF ACUTE HEART FAILURE USING NITROUS OXIDE AND CHRONIC HEART FAILURE USING BOTULINUM TOXIN | Final Rejection | Penland Foundation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy